An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
NCT07620392
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Rheumatoid Arthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- West Broward Rheumatology Associates, Inc. · Tamarac, FL
Louisiana · 1
- Accurate Clinical Research Inc. · Lake Charles, LA
Texas · 2
- Accurate Clinical Management LLC · Houston, TX
- DM Clinical Research · Tomball, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.